PADAMOLOGY Q+A
Questions that come up.
Answers that make sense.
Straightforward answers to questions about clinical research, medical monitoring, oncology development, careers, and the industry.
Q: Why do early oncology trials have so many protocol amendments?
Frequent protocol amendments can look like a sign that something went wrong. In early oncology development, they’re often a reflection of what the study is learning.
Q: Why do early phase oncology trials rarely go exactly as planned?
Early-phase oncology trials are designed around what we know at the start—but new information emerges quickly. Here’s why adaptation is often part of the process.
Q: Why can endpoints in oncology trials sometimes be misleading?
Endpoints help us measure whether a treatment is working, but they don’t always tell the whole story. Here’s why interpreting them in oncology requires context.
Q: Why are oncology protocols so complicated?
Oncology protocols can be exceptionally complex. Here’s what drives that complexity—and why much of it is necessary to safely answer the questions a trial is designed to address.